The pathway that skips the predicate

A 510(k) runs on one question by default: is the new device as safe and effective as a predicate already on the market? FDA’s Safety and Performance Based Pathway answers a different question for a growing, but still narrow, list of device types — does the new device meet performance criteria FDA has already published itself, with no predicate comparison at all.

An expansion of the abbreviated 510(k), not a new statute

FDA finalized the pathway’s framework guidance in early 2019, under docket FDA-2018-D-1387, as an expansion of the existing abbreviated 510(k) program — the same mechanism that already let a submitter rely on a recognized consensus standard or a special-controls guideline instead of raw side-by-side testing. Nothing in the pathway rewrites the governing statute’s substantial-equivalence standard. What changes is the evidence FDA will accept as proof: meet FDA’s own numbers for the device type, and the agency can find equivalence without ever naming a predicate to compare against. The review goal attached to that finding is the same 90 FDA days as an ordinary 510(k) — the pathway was never sold as a faster clock. What it buys is a narrower evidentiary burden, not less calendar time, and a submission that still falls short on one criterion gets the same additional-information cycle any other 510(k) would.

Eligible is a guidance, not a description

The pathway opened in 2019 with four device types — conventional Foley catheters, cutaneous electrodes for recording purposes, orthopedic non-spinal bone screws and washers, spinal plating systems. It has grown since, guidance by guidance, into more than a dozen types spanning dental, orthopedic, and ophthalmic devices — dental cements, denture base resin, surgical sutures, soft hydrophilic contact lenses among them. Each one reached the list the same way: FDA wrote and finalized a standalone guidance naming the exact performance criteria and the test methods a submission has to run to show it meets them, down to the standard and the acceptance value. A device type that looks just as well-understood as the ones already listed is not eligible until FDA has done that specific writing — “simple” and “on the list” are not the same determination, and only the agency makes the second one.

The shortcut isn’t earned by how well-understood a device is. It’s earned by whether FDA has already written the criteria down.

The practice

Before a submission assumes this pathway applies, confirm the device type carries a finalized, device-specific performance-criteria guidance today — not a device type that merely resembles one that does. openFDA’s classification record carries no field marking pathway eligibility, the same gap as ASCA accreditation and the Third Party Review program; the only authoritative answer is FDA’s own current list, read on the date of filing, not from memory of what it held a year ago. And meeting the pathway’s own criteria is still a choice, not a shortcut around judgment: a device that cannot actually meet the published numbers has to fall back to an ordinary predicate comparison, no matter how much paperwork the pathway would have saved, and nothing stops a submitter from running the pathway’s own testing first and keeping a conventional predicate in reserve in case it doesn’t clear every threshold. This is regulatory intelligence and method, never regulatory advice about whether a specific device qualifies for the pathway today.